Impurity Isolation and Identification

Impurity Isolation and Identification

BOC Sciences’ pharmaceutical separation and purification team are committed to the separation and identification of various impurities in the process of pharmaceutical research. Our experts are highly recognized by customers with their rich experience and problem-solving skills.

Main-types-and-sources-of-drug-impuritiesFigure 1. Main types and sources of drug impurities.

Our Conventional Services for Impurity Isolation and Identification

Impurity control is one of the core contents of drug quality control, and impurity research runs through the whole process of drug research and development. The isolation and identification of drug impurities are the most direct means for the study of impurities, and the separated impurities can be used for an in-depth study of qualitative, quantitative and safety. BOC Sciences provides comprehensive impurity isolation and identification services.

  • Impurities - Quantitative

To achieve quantitative analysis of impurities, we can separate impurities to obtain single components of impurities with good purity. We can add additional tests for impurities, including residual solvent (GC) and water content (Karl Fischer). 

Testing itemSpecificationResult
AppearanceBrown viscous gelConforms
Purity (by HPLC)≥ 95%95.1%
1HNMR, MS, IRConforms to structureConforms
Water content (by KF)-0.6%
Ethyl acetate residue (by GC)-3.81%
ConclusionThe products compiles with the given specification
Storage2 -8 °C. Air sensitive. Keep in a inert atmosphere
  • Impurities – Qualitative

We can use HPLC, LC-MS, IR, UV-Vis, 1HNMR, 13CNMR, etc. to qualitatively analyze impurities for identification purposes.

Analytical-technique

BOC Sciences’ Unique Technology

Liquid chromatography is widely used in downstream process crossing several industries. The technology becomes standard separation process to remove impurities or undesirable chemicals. Normally, the products are separated by affinity or hydrophobicity interaction with chosen functional columns. However, the state-of-art approach is limited in large biomolecules separation because of the lack of control in pore size. In fact, although size exclusion separation provides higher resolution, the technique is seldom used in the processing step because of the high pressure needed.

In addition to the conventional impurity isolation and identification techniques, we provide an alternative method to remove small molecular impurities below six angstrom with 100 times larger throughput. The technology is developed based on patented materials possess well-defined six angstrom porosity to identify products from impurities. Moreover, the chromatography column is further designed to achieve 100 times better throughput.     

The patented materials are self-assembled, highly symmetrical, ultrasmall inorganic cages directed by surfactant micelles, developed by research team at Cornell University.

self-assembled-patented-materialsFigure 2. a. Reconstructed dodecahedral silicage. b. Its three most unique projections.

This new technology can be used for removal of precursor or small molecular impurities under 6 angstrom, such as carcinogens, degradation products and other unknown impurities. Our initial proof-of-concept experiment has successfully demonstrated the viability of the technology for the separation of small molecule impurities that have recently led to recalls due to the unacceptable level of NDMA contaminations in the high-blood pressure drug, Ibesartan.

Illustration-of-the-mechanism-of-removing-NDMA-from-IrbesartanFigure 3. Illustration of the mechanism of removing NDMA from Irbesartan.

Note:

NDMA has attracted wide attention as being highly hepatotoxic and a known carcinogen in lab animals. High levels of exposure can cause reduced function of the kidneys and lungs. To date, NDMA has caused several recalls and warnings of successful drugs on the market, including Valsartan, Losartan, Irbesartan, Ranitidine and Metformin.

The experiment results show that the genotoxic impurity, NDMA in drug products was removed more than 99% (from 2000 ppm to < 1 ppm) by our new technology and the concentration went down below FDA’s daily allowance intake. At the same time, the yield of active pharmaceutical ingredient retained more than 90%. The measurements were conducted by following FDA published GC methods. Lower concentration can be achieved by repeating the separation process.

Efficiency-of-impurity-NDMA-removal Figure 4. Efficiency of impurity NDMA removal.

Through this technology, we can adjust the porosity of silicages to achieve specific separation purpose, we are now offering services for impurities removal, API purification and product upgrade. Please feel free to contact us if our new technology can help you.

Why Choose BOC Sciences?

  • BOC Sciences has a comprehensive literature retrieval system, a number of drug analysis technology platforms, familiar with drug impurity analysis, drug declaration and other relevant laws and regulations, efficient collaborative technical service capabilities.
  • BOC Sciences is equipped with a variety of analytical instruments and equipment, which can develop suitable methods for drug impurities with different chemical properties to achieve the appropriate detection limit in order to achieve the purpose of methodology and analytical detection.
  • BOC Sciences’ new technology can be used to develop research methods for many types of genotoxic impurities, such as azides, hydrazines, benzene sulfonates, p-benzene sulfonates, methylbiphenyls, valeryl chloride, etc. The methods are applicable to different regulatory requirements such as USP, EP, and more.
  • BOC Sciences can provide the isolation and identification of more than 10,000 impurities, enabling quantitative and qualitative analysis of impurities.

References

  1. Smith, R. J., & Webb, M. L. (Eds.). (2008). Analysis of drug impurities. John Wiley & Sons.
  2. Qiu, F., & Norwood, D. L. (2007). Identification of pharmaceutical impurities. Journal of liquid chromatography & related technologies, 30(5-7), 877-935.
  3. Ma, K., Gong, Y., Aubert, T. et al. (2018). Self-assembly of highly symmetrical, ultrasmall inorganic cages directed by surfactant micelles. Nature, 558, 577-580
Online Inquiry
Verification code